Bayer agrees to buy Perfuse Therapeutics in deal worth up to USD 2.45 billion

  • Bayer agreed to acquire Perfuse Therapeutics, gaining full rights to PER-001, a Phase II small-molecule endothelin receptor antagonist for glaucoma and diabetic retinopathy.
  • Deal value up to USD 2.45 billion, including USD 300 million upfront and additional development, regulatory, and commercial milestones tied to success criteria.
  • Transaction adds a potential disease-modifying ophthalmology program as Bayer looks to expand beyond intraocular-pressure lowering approaches in glaucoma.
  • Closing conditions include antitrust clearances and Perfuse stockholder approvals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via Business Wire (Ref. ID: 202605060230BIZWIRE_USPR_____20260505_BW596100) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.